Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Demant A/S
  6. News
  7. Summary
    DEMANT   DK0060738599

DEMANT A/S

(DEMANT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

2020-13: Financial calendar 2022

11/16/2021 | 07:49am EST

Company announcementno 2021-15

16 November 2021

Financial calendar 2022

 

27 January

Deadline for submission of items for the agenda of the annual
general meeting*

18 January to 7 February

 

Quiet period prior to publication of Annual Report 2021

8 February

 

Annual Report 2021

10 March

 

Annual general meeting

12 April to 2 May

 

Quiet period prior to publication of Interim Management Statement

3 May

 

Interim Management Statement

26 July to 15 August

 

Quiet period prior to publication of Interim Report 2022

16 August

 

Interim Report 2022

19 October to 8 November

 

Quiet period prior to publication of Interim Management Statement

9 November

 

Interim Management Statement

*Please note that if a shareholder would like to have a specific item included in the agenda for the general meeting on 10 March 2022, a written proposal must be submitted to the Board of Directors no later than six weeks prior to the annual general meeting, which means that proposals must reach the Board of Directors no later than 27 January 2022.

 

Further information:

Mathias Holten Møller, Head of Investor Relations

Phone +45 3917 7300

www.demant.com

 

 

Contacts

  • Mathias Holten Møller, Director, Head of Investor Relations, +45 3913 8827, msmo@demant.com

About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.

Attachments

  • 2021-15 Financial calendar 2022.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases

All news about DEMANT A/S
01/03DEMANT A/S : Transactions with Demant shares by managers and closely related parties
AQ
2021DEMANT A/S : Update on voluntary field corrective action
AQ
2021Demant A/S Announces Update on Voluntary Field Corrective Action
CI
2021William Demant Foundation donates DKK 3.5 million to UNICEF to help fight coronavirus
AQ
20212020-13 : Financial calendar 2022
AQ
2021Demant A/S Provides Earnings Guidance for the Second Half of the Year 2021
CI
2021DEMANT A/S : Interim Management Statement
AQ
2021Demant A/S Revises Earnings Guidance for the Year 2021
CI
2021DEMANT A/S : 3rd quarter results
CO
2021DEMANT A/S : Halts Sales for Cochlear Implants Amid Performance Issues
MT
More news
Analyst Recommendations on DEMANT A/S
More recommendations
Financials
Sales 2021 18 527 M 2 825 M 2 825 M
Net income 2021 2 510 M 383 M 383 M
Net Debt 2021 8 510 M 1 297 M 1 297 M
P/E ratio 2021 28,2x
Yield 2021 -
Capitalization 72 206 M 11 016 M 11 008 M
EV / Sales 2021 4,36x
EV / Sales 2022 3,97x
Nbr of Employees 17 556
Free-Float -
Chart DEMANT A/S
Duration : Period :
Demant A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEMANT A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 301,70 DKK
Average target price 337,27 DKK
Spread / Average Target 11,8%
EPS Revisions
Managers and Directors
S°ren Nielsen President & Chief Executive Officer
RenÚ Schneider Chief Financial Officer
Niels Bj°rn Christiansen Chairman
Benedikte Leroy Independent Director
Lars S°ren Rasmussen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
DEMANT A/S-9.85%11 009
STRAUMANN HOLDING AG-19.05%27 207
SONOVA HOLDING AG-10.12%21 861
COCHLEAR LIMITED-7.07%9 488
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.-9.14%3 250
ÖSSUR HF.-5.44%2 572